TSS
APRE icon

Two Sigma Securities’s Aprea Therapeutics APRE Stock Holding History

Two Sigma Securities’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,500
Closed -$10.3K – 1713
2026
Q1 		$10.3K Buy
+13,500
New +$10.6K ﹤0.01% 1461
2021
Q3 		– Sell
-598
Closed -$58K – 1536
2021
Q2 		$58K Buy
+598
New +$55.3K ﹤0.01% 1386

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Two Sigma Securities's APRE Position: Q2 2026 in Review

Two Sigma Securities sold out of Aprea Therapeutics (APRE) in Q2 2026, closing a stake of 13,500 shares — an estimated $10.3K sold.

Two Sigma Securities first reported a position in APRE in Q2 2021 and held it in 2 quarters. The position peaked at $58K in Q2 2021. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

  • Two Sigma Securities reported no remaining Aprea Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Securities sold 13,500 Aprea Therapeutics shares in Q2 2026, an estimated $10.3K.
  • Two Sigma Securities first reported a position in Aprea Therapeutics in Q2 2021 and held it in 2 quarters.
  • Two Sigma Securities's Aprea Therapeutics position peaked at $58K in Q2 2021.
  • 28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Two Sigma Securities's 13F filing for Q2 2026, filed 14 Aug 2026.